Coultreon Biopharma (fka Onco3R Therapeutics), a Leuven, Belgium-based biotechnology company developing therapies in immunology, raised $125M in Series A funding.
The round was Sofinnova Investments, Forbion and Novo Holdings with participation from Galapagos, Regeneron Ventures, Balyasny Asset Management, Luma Group, Samsara BioCapital, Longwood Fund and Finchley Healthcare Ventures.
The company intends to use the funds to support the further clinical development of Coultreon’s lead immunology program, COL-5671 (formerly O3R-5671), a highly selective, oral once-daily SIK3 inhibitor currently in Phase 1 studies.
Led by CEO Pierre Raboisson, Coultreon Biopharma develops therapies targeting clinically-validated pathways across immunology and metabolic diseases. The company leverages expertise in disease biology, drug discovery, and translational science to select the optimal therapeutic modality to address underlying disease biology with therapies. Coultreon’s pipeline is focused on salt-inducible kinase (SIK) biology and selectively modulating key inflammatory pathways to deliver broader and more durable disease control.
Its lead program, COL-5671, is a highly selective SIK3 inhibitor in clinical development for autoimmune diseases, with potential applicability across multiple immune-mediated conditions.
Don’t just read the news. Own the data. Stop manually tracking deals. Access this round and over 100 others this week—in our structured Master Database (XML) + Weekly Intelligence PDF. 👉 [Access FinSMEs Intelligence Hub]
FinSMEs
28/04/2026